NCT00070759View on ClinicalTrials.gov

Daclizumab to Treat Non-Infectious Sight-Threatening Uveitis

PHASE2CompletedINTERVENTIONAL

Enrollment

6

Participants

Timeline

Start Date

October 6, 2003

Study Completion Date

October 2, 2006

Conditions

Uveitis

Interventions

DRUG

Daclizumab

Trial Locations (1)

20892

National Eye Institute (NEI), Bethesda

All Listed Sponsors

lead

National Eye Institute (NEI)

NIH

NCT00070759 - Daclizumab to Treat Non-Infectious Sight-Threatening Uveitis | Biotech Hunter | Biotech Hunter